Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01247194 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1
A Phase 1 study, sponsored by Presidio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01247194 is a Phase 1 study that has completed, run by Presidio Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01247194, a Phase 1 study, has completed, sponsored by Presidio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
Interventions
- DRUG Placebo
- DRUG PPI-461
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01247194
The ClinicalTrials.gov registry entry for NCT01247194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Presidio Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01247194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01247194 about?
NCT01247194 is a clinical study titled "A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1". The purpose of the study is to assess the safety, tolerability, antiviral effects, and pharmacokinetics of PPI-461 in patients with chronic hepatitis C virus genotype 1 infection.
What is the current status of trial NCT01247194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01247194?
The interventions under investigation include: Placebo (DRUG), PPI-461 (DRUG).
Who is sponsoring clinical trial NCT01247194?
This trial is sponsored by Presidio Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.